Micromet Trading over 13% Higher on the Session after Positive Clinical Results

Data to be presented tomorrow at the 16th Annual Meeting of the European Hematology Association in London, UK, show that Micromet's blinatumomab produced a high complete remission rate in adult patients with acute lymphoblastic leukemia who had relapsed following treatment with standard therapy.1 Blinatumomab is the most advanced of a new class of agents called BiTE antibodies, designed to harness the body's T cells to kill cancer cells. Read more here.